Biotech Bros

This week on the podcast, Agustin reflects on the biotech sector and the recent price fluctuations in $XBI and highlights while there are several zombie companies that don't have long term potential. Despite these circumstances, $AFMD and $LPTX are exceptions that warrant more capital. Additionally, he reflects on the emergence of a new Covid variant and what that means for manufacturers, investors, and public health officials. 

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

As part of the multi-part series on Natural Killer Cell Therapies, this week on the podcast, Agustin discusses $AFMD. He explains the  company's technology, pipeline, and recent catalysts. Additionally, he addresses some key questions including the monotherapy potential of AFM13 and AFM24 and where Affimed stands relative to other companies within the NK cell therapy space.  

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

On this bonus episode Agustin sits down and speaks with Robert Foster, current CEO of Hepion Pharmaceuticals ($HEPA) and previous co-founder of Aurinia Pharmaceuticals ($AUPH) . In this interview, they discuss multiple topics from Robert's previous experience at Aurinia and how he is leveraging those insights to guide drug development at Hepion. They also speak on the NASH landscape and how Hepion is looking to position itself within the market. For access to the video interview make sure to check out my youtube channel later this week!


Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent news of oral therapeutics to help treat Covid and what this means going forward for vaccine manufactures. Additionally, he addresses concerns around $NVAX and $GTBP. Finally, he briefly highlights two companies that are looking to present at ASH and what their initial data might suggest going forward

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week's episode is Agustin's conversation with GT Biopharma CEO Anthony "Tony" Cataldo. On this episode they discuss the future of natural killer cell therapies and therapeutics including what makes $GTBP such a compelling company compared to others within this competitive space. 

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the recent data readouts of two allogeneic cell therapy companies. The cell therapy space is heating up and in this episode Agustin addresses some of the pros and cons associated with each of the gene-editing platform technologies currently in development

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses valuations in the biotech market including the CRISPR companies. Additionally, he shares updates on  past #picksoftheweek and highlights how $NVAX finally has submitted their data for regulatory approval to the WHO.  

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin highlights key readouts from ESMO. In particular he provides context to $LPTX's recent gastric cancer readout and highlights how $CRDF could have a best in class KRAS Colon Cancer Drug. 

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin celebrates the acquisition of Trillium Therapeutics, a previous pick of the week, comments on the future acquisition prospects for other CD47 players (i.e. $ALXO/ALX Oncology) within the market, and shares his thoughts on the questionable data behind Cassava Sciences and there dubious efficacy claims. 


Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin reflects on the current investor sentiment of biotech in the capital markets, the Delta variant and where we stand with vaccine hesitancy, and shares his reaction to Fate Therapeutics ($FATE) and their data as part 1 of the multi-part natural killer cell therapy series.  

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com